Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives

Pharmaceuticals

Manja Kubeil¹  Michael Bachmann¹  Irma Ivette Santana Martínez¹  Holger Stephan¹  Klaus Kopka¹  Kellie L. Tuck² 

[1] Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany;School of Chemistry, Monash University, Melbourne, VIC 3800, Australia;

关键词: molecular imaging;    positron emission tomography;    single-photon emission computed tomography;    near-infrared fluorescence;   

DOI  :  10.3390/ph15040432

来源: DOAJ

【 摘 要 】

Molecular imaging offers the possibility to investigate biological and biochemical processes non-invasively and to obtain information on both anatomy and dysfunctions. Based on the data obtained, a fundamental understanding of various disease processes can be derived and treatment strategies can be planned. In this context, methods that combine several modalities in one probe are increasingly being used. Due to the comparably high sensitivity and provided complementary information, the combination of nuclear and optical probes has taken on a special significance. In this review article, dual-labelled systems for bimodal nuclear and optical imaging based on both modular ligands and nanomaterials are discussed. Particular attention is paid to radiometal-labelled molecules for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) and metal complexes combined with fluorescent dyes for optical imaging. The clinical potential of such probes, especially for fluorescence-guided surgery, is assessed.

【 授权许可】

Unknown